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Accepted 16 September 2008Conditioned medium (CM) from clonal sub-populations of the pancreatic cancer cell line,
MiaPaCa-2 with differing invasive abilities, were examined for their effect on in vitro
invasion. Conditionedmedium from Clone #3 (CM#3) strongly promoted invasion, while CM
from Clone #8 (CM#8) inhibited invasion in vitro. 2D DIGE followed by MALDI–TOF MS
analysis of CM#3 and CM#8 identified 41 proteins which were differentially regulated; 27
proteins were down-regulated and 14 proteins up-regulated in the invasion-promoting
CM#3 when compared to CM#8. Western blotting analysis confirmed the down-regulated
expression of gelsolin and the up-regulation of aldehyde dehydrogenase 1A1 in CM#3.
Down-regulation of aldehyde dehydrogenase 1A1 in Clone #3 CM and gelsolin levels in
Clone #8 CM by siRNA transfection revealed an important involvement of these proteins in
promoting and inhibiting invasion in these pancreatic cancer cell lines.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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Pancreatic cancer is one of the most lethal cancers and is the
8th leading cause of cancer-related deaths in Europe [1].
Pancreatic cancer is associatedwith poor prognosis, the rate of
mortality being similar to that of the rate of incidence.
All-stage 5-year survival rate is less than 5% [2,3]. Conven-
tional approaches including, surgery, radiation, chemotherapy
and combinations of these therapies, have had little effect on
the survival rate of patients diagnosed with pancreatic cancer.
Pancreatic cancer appears to be inherently resistant to a wide
variety of chemotherapeutic agents, which can differ greatly
and are unrelated with respect to molecular structure and
target specificity. The malignant progression, invasion and
metastasis of this cancer are complex and poorly understood.
In this study, we investigated the proteomic profile of proteins
from the conditioned media of two sub-clones of a pancreaticalsh).
er B.V. All rights reservedcancer cell line with varying in vitro invasive characteristics.
Proteins released by pancreatic tumour cellsmay be detectable
in bodily fluids such as urine, blood, serum and pancreatic
ductal juice. Such proteins could be useful in early diagnosis,
monitoring and perhaps even molecular classification of
pancreatic tumours [4]. Proteomic analyses of pancreatic
tissue, pancreatic juice as well as blood plasma and sera have
been reported [5]. The main biomarker currently available for
pancreatic cancer detection, CA19-9, has been demonstrated
to be quite sensitive and specific in the diagnosis of this
malignancy [6,7], however, this marker is not fully specific as
false-positive or false-negative findings occur in patients with
other gastrointestinal malignancies and also in patients with
benign disease, particularly when associated with obstructive
jaundice or cirrhosis, whichmay contribute to late diagnosis of
pancreatic cancer. Approximately 10% of the population with
the Lewis negative genotype are not able to produce CA 19-9,.
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gene that is involved in its synthesis [8]. Therefore, in a sub-set
of patients, CA 19-9 expression will be falsely low even in the
presence of advanced pancreatic cancer [9].
We previously isolated sub-clones of the human pancreatic
adenocarcinoma cell line, MiaPaCa-2. This cell line was
chosen as it displays modest invasion through matrigel, and
could be easily cultured as single cell colonies. Two sub-
clones, Clone #3 and Clone #8 displayed the largest differences
in invasion compared to the parental cell line andwere chosen
for further analysis.
In this study, we compared proteins in the conditioned
media of highly and poorly invasive sub-clones of the
pancreatic cancer cell line, MiaPaCa-2, and identified many
novel up-regulated and down-regulated proteins in ourmodel.
Furthermore, we investigated the functional role of aldehyde
dehydrogenase 1A1 and gelsolin in invasion by siRNA analysis
and determined that these proteins may have a novel role in
the invasive phenotype of pancreatic cancer.Fig. 1 –A. Invasion assays of Clone #3 under control conditions a
B. Invasion assays of Clone #8 under control conditions and conta
of invading cells was determined by counting the number of cell
average number of cells per field was then multiplied by a factor
magnification (calibrated using a microscope graticule)). Insert: C
determined by elution of insertswith 0.33% acetic acid and spectr
in triplicate. Statistics; *p≤0.05, **p≤0.01, ***p≤0.005 Student's t-t2. Materials and methods
2.1. Cell lines
Thehumanpancreatic cell lineMiaPaCa-2wasobtained fromthe
European Collection of Cell Cultures (ECACC, UK). BxPc-3, Panc-1
and AsPc-1 human pancreatic cancer cell lines were obtained
fromtheAmericanTypeCultureCollection (ATCC,Rockville,MD,
USA). Clone #3 and Clone #8were obtained by single cell dilution
in this laboratory. Briefly the parental cell line, MiaPaCa-2 was
diluted to a concentration of 3 cells/ml and 100 µl plated onto
each well of a 96-well plate. After 24 h each well was studied for
single cells, and allowed to grow into colonies. The colonieswere
then screened by invasion assay to assess their invasive abilities.
Cells were maintained in a humidified atmosphere containing
5% CO2 at 37 °C in DMEM supplemented with 5% FCS (Sigma-
Aldrich). All cell lines were free fromMycoplasma as tested with
the indirect Hoechst staining method.nd containing CM#3 and CM#8 in the invasion insert.
ining CM#3 and CM#8 in the invasion insert. The total number
s per field in 10 random fields, at 200× magnification. The
of 140 (growth area of membrane/field area viewed at 200×
olorimetric relative quantification of invading cells was also
ophotometrically quantified. All experimentswere performed
est.
Fig. 2 –Protein expression map (PEM) of differentially
regulated proteins in the comparison of CM#3 versus CM#8.
All protein numbers correspond to Tables 1 and 2.
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media
Clone #3 and Clone #8 monolayers were cultured in T175 cm3
flasks until approximately 60% confluent in culture medium.
Cells were then washed 3× with serum free (SF) DMEM and
incubated for 1 hwith SF DMEM. Cells werewashed 3× again in
SF DMEM, then placed in SF DMEM for 72 h. At the time
of collection, cellular debris was removed by centrifugation
and filtration through a 0.22 µm filter; aliquots were frozen
at −80 °C until analysed.
2.3. Invasion assays
Invasionassayswere performedusing anadaptedmethod [10].
Matrigel was diluted to 1 mg/ml in serum free DMEM. 100 µl of
matrigel was placed into each insert (Falcon) (8.0 µm pore size)
in a 24-well plate (Costar). The coated inserts were incubated
overnight at 4 °C. The following day, the matrigel was allowed
to polymerise at 37 °C for 1 h. The inserts were then washed
with DMEM, 100 µl of 1×105/100 µl cells in complete DMEM and
100 µl of CM supplementedwith 5% serumwas added onto the
insert. 250 µl of total DMEM:250 µl CM supplemented with 5%
serum was added to the 24-well plate. After 24 h incubation,
the inside of the insert was wiped with a wet cotton swab. The
under surface was gently rinsed with PBS and stained with
0.25% crystal violet for 10 min, rinsed again with sterile water
and allowed to dry. To determine the total number of invading
cells, the inserts were then viewed under the microscope and
the number of cells per field in 10 random fields, were counted
at 200× magnification. The average number of cells per field
was then multiplied by a factor of 140 (growth area of
membrane/field area viewed at 200×magnification (calibrated
using a microscope graticule)). Colorimetric quantification of
invasion was determined by eluting the crystal violet stain
solution with 33% acetic acid extraction buffer and the
absorbance was read with a Bio-Tek plate reader (Becton
Dickinson Labware) at 570 nm and a reference wavelength of
620 nm. The mean values were obtained from a minimum of
three individual experiments andwere subjected to t-tests. All
experiments were performed in triplicate.
2.4. Sample preparation and protein labelling
Six individual 50 ml samples for both CM#3 and CM#6
(biological replicates and technical replicates/CM of cell line)
were concentrated using a 10,000 molecular weight cut-off
(Millipore); samples were cleaned-up using a ready-prep 2D
clean-up kit (Bio-Rad). Protein concentration was determined
using the BCA protein assay kit (Bio-Rad). CM samples were
labelled with N-hydroxy succinimidyl ester-derivatives of the
cyanine dyes Cy2, Cy3 and Cy5 [11]. Typically, 50 µg of the CM
was minimally labelled with 200 pmol of either Cy3 or Cy5 for
comparison on the same 2-D gel. Labelling reactions were
performed on ice in the dark for 30 min and then quenched
with a 50-fold molar excess of free lysine to dye for 10 min on
ice. A pool containing equal amounts of all samples was also
prepared and labelled with Cy2 to be used as a standard on all
gels to aid image matching and cross-gel statistical analysis.
The Cy3 and Cy5 reverse labelling reactions (50 µg of each)from each CM sample were mixed and run on the same gels
with an equal amount (50 µg) of Cy2-labelled standard.
2.5. Protein separation by 2-DE and gel imaging
Immobilised 24 cm linear pH gradient (IPG) strips, pH 3–11,
were rehydrated in rehydration buffer (7 M urea, 2 M thiourea,
4%CHAPS, 0.5% IPG buffer, 50mMDTT) overnight, according to
manufacturer guidelines. IEF was performed using an IPGphor
apparatus (GE Healthcare) for 40 kV/h at 20 °C with resistance
set at 50mA. Stripswere equilibrated for 20min in 50mMTris-
HCL, pH 8.8, 6 M urea, 30% v/v glycerol, 1% w/v SDS containing
65 mM DTT and then for 20 min in the same buffer containing
240 mM iodoacetamide. Equilibrated IPG strips were trans-
ferred onto 18×20 cm 12.5% uniform polyacrylamide gels
poured between low fluorescence glass plates. Strips were
overlaid with 0.5% w/v low melting point agarose in running
buffer containingbromophenol blue. Gelswere runat 2.5W/gel
for 30 min and then 100 W total at 10 °C. All the images were
collected on a Typhoon 9400 Variable Mode Imager (GE
Healthcare). Statistics and quantification of protein expression
were carried out in DeCyder software (GE Healthcare).
2.6. Spot digestion and MALDI–TOF analysis
Excision of protein spots, trypsin digestion and protein
identification by MS analysis using an Ettan MALDI–TOF Pro
(GE Healthcare) were performed. Preparative gels containing
300 µg of protein were fixed in 30% v/v methanol, 7.5% v/v
acetic acid overnight and washed in water, and total protein
was detected by post-staining with CBB and Deep purple stain
(Molecular Probes) for 3 h at room temperature. Excess dye
was removed bywashing twice inwater, and gels were imaged
using a Typhoon 9400 VariableMode Imager (GE Healthcare) at
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stain. The subsequent gel image was imported into the BVA
module of DeCyder software and was matched to images
generated from DIGE analysis. Spots of interest were selected
and confirmed using this software for subsequent picking
using an Ettan Spot Picker. Gel plugs were placed into a
presiliconised 1.5 ml plastic tube for destaining, desalting and
washing steps. The remaining liquid above the gel plugs was
removed and sufficient ACN was added in order to cover the
gel plugs. Following shrinkage of the gel plugs, ACN was
removed and the protein containing gel pieces were rehy-
drated for 5 min with a minimal volume of 100 mM
ammonium bicarbonate. An equal volume of ACN was
added, and after 15 min of incubation the solution wasTable 1 – 2D DIGE and MALDI–TOF MS identification of down-r
Clone #3
No. Protein name Gene
symbol
Protein AC
number
1 Gelsolin isoform b (a) GSN gi|38044288|
2 Gelsolin isoform b (b) GSN gi|38044288|
3 Gelsolin isoform b (c) GSN gi|38044288|
4 Gelsolin isoform b (f) GSN gi|38044288|
5 Gelsolin isoform b (d) GSN gi|38044288|
6 Gelsolin isoform b (g) GSN gi|38044288|
7 Gelsolin (amyloidosis: Finnish type) GSN gi|55960299|
8 Pro-MMP-2TIMP2 complex TIMP2 gi|22218678|
9 Beta actin (a) ACTB gi|15277503|
10 Nucleoside-diphosphate kinase 2
isoform
NDPK2 gi|66392203|
11 Beta actin (c) ACTB gi|15277503|
12 Proteasome activator reg (alpha) PSME1 gi|2780883|
13 Beta actin (b) ACTB gi|15277503|
14 Heat shock protein 90-alpha
(HSP86)
HSP86 gi|92090606|
15 Phosphoglycerate kinase 1 (a) PGK1 gi|48145549|
16 Thioredoxin peroxidase PRDX2 gi|9955016|
17 Phosphoglycerate kinase 1 (b) PGK1 gi|48145549|
18 Phosphoglycerate kinase 1 (c) PGK1 gi|48145549|
19 Heat shock 70 kDa protein 8
isoform 2 (b)
HSPA8 gi|62896815|
20 Beta actin (d) ACTB gi|15277503|
21 NM23-H1 NME1 gi|29468184|
22 Triosephosphate isomerase TPI1 gi|999893|
23 Heat shock 70 kDa protein 8
isoform 2 (a)
HSPA8 gi|62896815|
24 S-adenosylhomocysteine
hydrolase
AHCY gi|178277|
25 Malate dehydrogenase cytosolic MDH1 gi|7431153|
26 Heat shock 70 kDa protein 8
isoform 2 variant (c)
HSPA8 gi|62896815|
27 Nucleoside phosphorylase NP gi|58176568|removed from the gel plugs and the samples were dried for
30 min using a vacuum centrifuge. Individual gel pieces were
then rehydrated in digestion buffer (12.5 ng trypsin per μl of
10% ACN, 40 mM ammonium bicarbonate) to cover the gel
pieces. Exhaustive digestion was carried out overnight at
37 °C. After digestion, the samples were centrifuged at
12,000 ×g for 10 min using a bench top centrifuge. The
supernatant was carefully removed from each sample and
placed into clean plastic tubes. Samples were stored at −80 °C
until analysed by M.S. For spectrometric analysis, mixtures of
tryptic peptides from individual samples were desalted using
Millipore C-18 Zip-Tips (Millipore) and eluted onto the sample
plate with the matrix solution (5 mg/ml CHCA in 50% ACN/
0.1% TFA v/v). Mass spectra were recorded using the MALDI–egulated proteins in the conditioned media of the invasive
Theoretical
pI/Mw
%
Coverage
Fold
change
Molecular function
5.6/80.9 17.9 −21.0⁎⁎⁎ Structural constituent of the
cytoskeleton
5.6/80.9 24.4 −15.2⁎⁎⁎ Structural constituent of the
cytoskeleton
5.6/80.9 18.6 −10.7⁎⁎⁎ Structural constituent of the
cytoskeleton
5.6/80.9 15.2 −6.4⁎⁎⁎ Structural constituent of the
cytoskeleton
5.6/80.9 18.3 −3.8⁎⁎⁎ Structural constituent of the
cytoskeleton
5.6/80.9 18.5 −3.4⁎⁎⁎ Structural constituent of the
cytoskeleton
5.9/86.0 9.5 −2.5⁎⁎⁎ Structural constituent of the
cytoskeleton
6.5/22.4 30.9 −1.8⁎⁎⁎ ECM structural constituent
5.6/40.5 36.6 −1.7⁎⁎⁎ Structural constituent of the
cytoskeleton
9.3/30.5 21.7 −1.7⁎⁎ Transcription factor activity
5.6/40.5 24.4 −1.6⁎⁎⁎ Structural constituent of the
cytoskeleton
7.1/16.3 44.3 −1.5⁎⁎⁎ Ubiquitin-specific protease
activity
5.6/40.5 24.2 −1.5⁎⁎⁎ Structural constituent of the
cytoskeleton
4.9/85.0 24.5 −1.5⁎⁎⁎ Chaperone activity
8.6/44.9 25.7 −1.4⁎⁎⁎ Catalytic activity
5.7/21.6 28.4 −1.4⁎⁎⁎ Peroxidase activity
8.6/44.9 25.7 −1.4⁎⁎⁎ Catalytic activity
8.6/44.9 27.3 −1.4⁎⁎⁎ Catalytic activity
5.6/53.6 16.8 −1.3⁎⁎⁎ Heat shock protein activity
5.6/40.5 27.3 −1.3⁎⁎⁎ Structural constituent of the
cytoskeleton
5.4/19.8 27.1 −1.3⁎⁎⁎ Catalytic activity
6.5/26.8 29.0 −1.3⁎⁎⁎ Isomerase activity
5.6/53.6 28.8 −1.3⁎⁎⁎ Heat shock protein activity
6.0/48.2 10.6 −1.3⁎⁎⁎ Hydrolase activity
5.9/36.6 20.1 −1.2⁎⁎⁎ Catalytic activity
5.6/53.6 19.7 −1.2⁎⁎⁎ Heat shock protein activity
6.5/32.2 36.1 −1.2⁎⁎⁎ Phosphorylase activity
Table 2 – 2DDIGE andMALDI–TOFMS identification of up-regulated proteins in the conditionedmedia of the invasive Clone #3
No. Protein name Gene
symbol
Protein AC
number
Theoretical
pI/Mw
%
Coverage
Fold
change
Molecular function
28 Capping protein, muscle Z line,
alpha 1
CAPZA1 gi|12652789| 5.4/33.0 39.9 1.2⁎⁎⁎ Structural molecule activity
29 Beta actin (g) ACTB gi|15277503| 5.6/40.5 30.6 1.2⁎ Structural constituent of the
cytoskeleton
30 Beta actin (f) ACTB gi|15277503| 5.6/40.5 24.4 1.2⁎ Structural constituent of the
cytoskeleton
31 Glycerate-3-phosphate
dehydrogenase
GAPDH gi|31645| 8.4/36.2 19.4 1.2⁎⁎ Catalytic activity
32 Beta actin (e) ACTB gi|15277503| 5.6/40.5 24.5 1.2⁎ Structural constituent of the
cytoskeleton
33 Galectin-1 LGALS1 gi|56554350| 5.1/14.8 38.1 1.3⁎⁎⁎ Receptor binding
34 Mu-protocadherin isoform MUCDHL gi|62020550| 4.8/88.4 18.2 1.3⁎⁎⁎ Cell adhesion molecule
activity
35 Pi glutathione transferase GSTP1 gi|34811304| 5.7/23.4 36.4 1.3⁎⁎⁎ Glutathione transferase
activity
36 Elongation factor EEF1A1 gi|15277711| 9.3/46.5 12.1 1.4⁎⁎⁎ Translation regulator
activity
37 Alpha enolase (b) ENO1 gi|2661039| 7.0/47.4 28.6 1.5⁎⁎⁎ Catalytic activity
38 Peroxiredoxin 1 PRDX1 gi|55959887| 6.4/19.1 53.2 1.5⁎⁎⁎ Peroxidase activity
39 Alpha enolase (a) ENO1 gi|2661039| 7.0/47.4 15.5 1.5⁎⁎⁎ Catalytic activity
40 Mitochondrial malate
dehydrogenase
MDH2 gi|12804929| 9.4/35.9 37.0 1.6⁎⁎⁎ Catalytic activity
41 Aldehyde dehydrogenase 1A1 ALDH1A1 gi|2183299| 6.3/55.4 18.4 21.0⁎⁎⁎ Aldehyde dehydrogenase
activity
The theoretical isoelectric point (pI) and molecular weight (Mw) were calculated from the sequence of the protein in the database. Isoforms of
the same protein are referred to as (a), (b) etc. The percentage coverage is the amount of the protein sequence covered by the matched peptides.
Statistical analysis between replicates is referred to as; ⁎p≤0.05, ⁎⁎⁎p≤0.01, ⁎⁎⁎p≤0.005.
Fig. 3 –Term-ranking GO categories. Representation of the 10
top-ranked functional categories, using GO terms that are
enriched in all significantly differentially expressed proteins
identified between CM#3 and CM#8.
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the following parameters: accelerating voltage 20 kV; and
pulsed extraction; on (focus mass 2500). Internal calibration
was performed using anti-analysis peaks at m/z 842.50, m/z
2211.104 and external calibration was performed using Pep4
mix. The mass spectra were analysed using MALDI evaluation
software (GE Healthcare), and protein identification was
achieved with the PMF Pro-Found search engine.
2.7. Western blot
Protein concentrations were determined using the Bio-Rad
protein assay (Bio-Rad). 35 µg of protein was separated by 7.5%
SDS–PAGE under reducing conditions. Proteins were trans-
ferred to nitrocellulose membrane. Membranes were blocked
at 4 °C overnight in TBS (25mM Tris-HCl, pH 7.4, 150mMNaCl,
2.7 mM KCl) containing 5% (w/v) lowfat milk powder.
Membranes were probed with monoclonal antibodies, anti-
gelsolin (G4896, Sigma) and anti-aldehyde dehydrogenase 1A1
(488–501, Calbiochem). Membranes were washed 3× for 5 min
with PBS-Tween-20 (0.5%) and incubated with secondary
antibodies, anti-mouse and anti-goat obtained from Sigma
for 1 h at RT and washing step was repeated. Detection was
performed with Luminol reagent (Santa Cruz Biotechnology).
2.8. SiRNA transfection
For each set of siRNA transfections carried out, a non-treated
control and a scrambled (SCR) transfection control (Ambion, #
17010) were used. SiRNA experiments were set up using 2 µl
NeoFx (Ambion, AM4511), to transfect 30 nM siRNA at a celldensity of 3×105/well/ml of a 6-well plate. Cells were
transfected with two different GSN siRNAs, both of which
target variant 1, isoform a and variant 2, isoform b of GSN
(NM_000177 Exon 5, NM_198252 Exon 6: Sequence GCAAUCG-
GUAUGAAAGACUtt (sense), Ambion, #8127) and (NM_000177
Exon 2, NM_198252 Exon 3: Sequence GCUGAGGAACG-
GAAAUCUGtt (sense), Ambion, #8031) and with three differ-
ent ALDH1A1 siRNAs targeting the ALDH1A1 isoform
(NM_000689 Exon 11, 12: Sequence GGAACAGUGUGGGU-
GAAUUtt (sense), Ambion, #106197), (NM_000689 Exon 9:
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#106196), and (NM_000689 Exon 4: Sequence GGGCCGUA-
CAAUACCAAUUtt (sense), Ambion, #106195). After 32 h, the
media were removed, washed 3× in SF DMEM and 1 ml of SF
DMEM was added onto the cells. The effects of siRNA
silencing were analysed on the SF CM after 48 and 72 h.
SiRNA transfected SF CM was collected, centrifuged and
filtered through a 0.22 µm filter. SiRNA transfected SF CMwas
concentrated using 10,000 molecular weight cut-off concen-
trators (Millipore); samples were cleaned-up using a ready-
prep 2D clean-up kit (Bio-Rad) and protein concentration was
determined using the BCA protein assay kit (Bio-Rad).
Western blot analysis was then carried out to assess efficient
transfection. All experiments were repeated in triplicate.
2.9. Statistical analysis
Student's t-test was used to identify the difference in mean
values between treated and non-treated samples. In siRNA
experiments, siRNA scrambled transfected cells were used as
control compared to siRNA treated samples. This was toFig. 4 –A.Western blot of two independent target siRNA-GSN knoc
loading between the samples. B. Invasion assay of Clone #8 cells
siRNA, CM#8 treated with GSN-siRNA (1) and CM#8 treated with
determined by counting the number of cells per field in 10 random
field was thenmultiplied by a factor of 140 (growth area of memb
a microscope graticule)). Insert: Colorimetric relative quantificatio
with 0.33% acetic acid and spectrophotometrically quantified. Exp
***p≤0.005.ensure no ‘off-target’ effects of the transfection procedure.
Non-treated controls were used to ensure scrambled siRNA
was having no effects and to normalise data. A p value of
≤0.05⁎ was deemed significant, p value≤0.01⁎⁎ was deemed
more significant, and p value≤0.005⁎⁎⁎ was deemed highly
significant.3. Results
3.1. Factors in conditioned medium alter invasive abilities
of pancreatic cancer cell lines
CM#3 enhanced invasion of Clone #3 by 1.8-fold (p=0.0008)
compared to an invasion assay control containing fresh
medium. Clone #3 containing CM#8 in the invasion assay
showed a 3.33-fold decrease in invasion (pb0.001) (Fig. 1A).
Fig. 1B shows that CM#3 significantly increased the invasion
(4.2-fold (p=0.005)) of Clone #8 compared to an invasion assay
control containing fresh medium. CM#8 caused a very slight
(1.1-fold) decrease in invasion of Clone #8 (p=0.7).kdowns in CM#8. Bip antibodywas used to demonstrate even
with the addition of CM#8 untreated control, CM#8 scrambled
GSN-siRNA (2) (n=3). The total number of invading cells was
fields, at 200×magnification. The average number of cells per
rane/field area viewed at 200×magnification (calibrated using
n of invading cells was also determined by elution of inserts
eriments performed in triplicate. Statistics; *p≤0.05, **p≤0.01,
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MALDI–TOF MS
Proteins found in CM#3 and CM#8 were analysed by 2-D
DIGE. Triplicate biological repeats were reverse labelled with
Cy3 and Cy5 dyes. All samples used in the experiment were
pooled and labelled with the internal dye, Cy2. Each sample
was compared internally to the same standard, to account
for any gel-to-gel variation. DeCyder image analysis merged
the Cy2, Cy3 and Cy5 images for each gel and detected spot
boundaries for the calculation of normalised protein abun-
dance. All paired images were then matched to generate
comparative cross-gel statistical analysis. Biological varia-
tion analysis of these spots showing greater than 1.2-fold
change in expression with a t-test score of b0.05, revealed 41
proteins significantly differentially regulated between CM#3
versus CM#8. Protein expression maps (PEM) of all identified
proteins are shown in Fig. 2 (position number corresponds toFig. 5 –A. Western blot of ALDH1A1 knockdown in CM#3 untreat
(2) and siRNA ALDH1A1 (3). B. Invasion assay of Clone #3 with ad
siRNA, CM#3 treated with ALDH1A1 siRNA (1), CM#3 treated with
(3) (n=3). The total number of invading cells was determined by
200×magnification. The average number of cells per field was the
area viewed at 200× magnification (calibrated using a microscop
invading cells was also determine by elution of inserts with 0.33%
number of invading cells were stained with 0.25% crystal violet,
quantified, to determine the relative number of invading cells. Ex
bar, 200μm. Statistics; *p≤0.05, **p≤0.01, ***p≤0.005.Tables 1 and 2). For protein identification, all proteins were
digested and identified at least twice from separate gels
with MALDI–TOF MS. An expectation value of b0.002 was
used for all reported identifications, which indicates a 0.2%
chance that the identification is random. Table 1 outlines
the down-regulated proteins in CM#3 compared to CM#8 and
Table 2 shows the proteins up-regulated in CM#3 compared
to CM#8.
3.3. Gene ontology enrichment analysis
Using DAVID gene ID tool software (http://david.abcc.ncifcrf.
gov), all the proteins differentially regulated in our model
were converted to their gene IDs. Gene ontology (GO STAT)
(http://gostat.wehi.edu.au/cgi-bin/goStat.pl) was then used
to classify the proteins and their corresponding genes into
gene categories. Enrichment of a particular ontology term,
for significantly expressed genes in response to the processed control, scrambled, siRNA ALDH1A1 (1), siRNA ALDH1A1
dition of CM#3 media (control), CM#3 media with scrambled
ALDH1A1 siRNA (2), CM#3 treated with ALDH1A1 siRNA
counting the number of cells per field in 10 random fields, at
nmultiplied by a factor of 140 (growth area ofmembrane/field
e graticule)). Insert: Colorimetric relative quantification of
acetic acid and spectrophotometrically quantified. The total
eluted with 0.33% acetic acid and spectrophotometrically
periments performed in triplicate. Magnification, 200×. Scale
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involved in the process. In our study, the process refers to
factors involved in invasion of pancreatic cancer. Using the
over-expression function of the software and false discovery
rate (Benjamini) statistics, 30 GO terms were found signifi-
cantly enriched in both the up-regulated and down-regu-
lated proteins list in CM#3 versus CM#8. The “glycolysis”
term achieved the highest degree of significance in both the
up-regulated and down-regulated gene class (p=0.005,
p=0.001). In the up-regulated class, “cytoplasm” (p=0.01),
“oxidoreductase activity” (p=0.01) and “intracellular part”—
(including cytoplasmic and nucleus proteins) (p=0.03) were
highly significant terms. In the down-regulated class,
“cytosol”—(no membranous or subcellular components)
(p=0.007), and “actin filament severing” (p=0.03) were also
significantly enhanced. Fig. 3 outlines the top ten ranked
functional categories using GO terms in the differentially
expressed proteins in the pancreatic cancer model.
3.4. Invasion inhibitory role of GSN by siRNA in CM#8
GSN, a down-regulated protein in CM#3 compared to CM#8 was
analysed to assess its functional involvement in pancreaticFig. 6 –A.Western blot of GSN and ALDH1A1 expression in pancr
used as loading control. B. Invasion assay of BxPc-3, Panc-1 and A
counting the number of cells per field in 10 random fields, at 200×
multiplied by a factor of 140 (growth area of membrane/field area
graticule)). Insert: Colorimetric relative quantification of invading
acetic acid and spectrophotometrically quantified. Experiments pcancer cell invasion. Fig. 4A shows the successful knockdownof
GSN in CM#8 by two independent siRNA targets relative to
control (untreated) and siRNA scrambled CM#8. The addition of
CMfromClone#8GSN-siRNA (1) ontoClone#8cells significantly
increased the invasive abilities of the cells by 1.3 fold (p=0.01).
CM fromGSN-siRNA (2) treated Clone #8 cells onto Clone #8 also
increased the invasiveness of the cells 1.5 fold (p=0.2) (Fig. 4B).
3.5. Invasion enhancement role of ALDH1A1 by siRNA in
CM#3
ALDH1A1, which is up-regulated in CM#3 compared to CM#8,
was knocked down in Clone #3 to assess its functional role in
pancreatic cancer cell invasion. Fig. 5A shows the efficient
knock down of ALDH1A1 in CM#3 by three independent
siRNAs. CM from ALDH1A1-siRNA treated Clone #3 cells was
added into the invasion assay of Clone #3. Reduction of
ALDH1A1 expression resulted in a significant decrease in
invasion of Clone #3. CM#3 ALDH1A1-siRNA (1) on Clone #3
reduced invasion 4.2-fold (p=0.01), ALDH1A1 siRNA (2)
decreased invasion 2.7-fold (p=0.003) and ALDH1A1 siRNA (3)
also significantly reduced the invasive abilities of Clone #3 2.5-
fold (p=0.02), compared to the scrambled control (Fig. 5B).eatic cancer cell lines, BxPc-3, Panc-1 and AsPc-1. β-actin was
sPc-1. The total number of invading cells was determined by
magnification. The average number of cells per fieldwas then
viewed at 200× magnification (calibrated using a microscope
cells was also determined by elution of inserts with 0.33%
erformed in triplicate.
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cancer cell lines
GSN and ALDH1A1 expression was detected through western
blot in three other human pancreatic cancer cell lines, BxPc-3,
Panc-1 and AsPc-1 (Fig. 6A). Fig. 6B shows the relative invasive
potential of the cell lines. Both BxPc-3 and Panc-1 expressed
low levels of GSN compared to AsPc-1, which is less invasive.
ALDH1A1 expression was stronger in BxPc-3 and Panc-1 than
in AsPc-1 which corresponds to the high invasive abilities of
BxPc-3 and Panc-1.4. Discussion
In this study, proteins were analysed from culture medium
conditioned by Clone #3 and Clone #8 in serum free conditions
(SF) (to reduce the abundance of bovine serum proteins in the
samples). 2D DIGE followed by MALDI–TOF MS analysis of SF
CM#3 and CM#8 resulted in identification of 41 differentially
expressed proteins. Bio-informatic analysis (GO STAT) was
applied to all differentially abundant proteins between CM#3
and CM#8. Gene ontology (GO STAT) classified the proteins
and their corresponding genes into gene categories. Although
membrane-bound and secreted proteins are more likely to be
cleaved and found in the circulation [12], our GO STAT analysis
determined that most up-regulated and down-regulated
proteins were involved in glycolysis, cytoplasm, cytosol and
intracellular part. Proteins, such as heat shock proteins and
actins, generally viewed as cytoplasmic, have been increas-
ingly implicated in extracellular functions [13,14]. Eukaryotic
protein secretion normally routes through the endoplasmatic
reticulum (ER) and Golgi, ending up in a secretory vesicle
fusing to the cell membrane. In addition, recent studies have
shown that the non-classical secretory pathway works
independently of the ER–Golgi network; the secreted proteins
do not enter the ER and have not been glycosylated [15]. Non-
classical secretion by cell lines of the cytosolic green
fluorescent protein (GFP) was shown experimentally [16];
export was not hampered by inhibitors of the classical
secretory pathway, such as monensin and brefeldin A. Martin
et al. [17] also identified many intracellular proteins from both
the cytoplasmic and nuclear compartments from proteomics
analysis of medium conditioned by the prostate cell line,
LNCaP. During cell culture in serum free conditions, some cells
will die, resulting in the release of intracellular proteins into
the media. These intracellular proteins could serve as viable
cancer-specific markers as cancer cells undergoing death can
release proteins which can be detected in the circulation [18].
During our analysis we observed very little difference in the
proliferation rate of cells grown in serum free conditions
versus normal cell culture, therefore cell death was not a
major contributor to the expression of intracellular proteins in
the CM. Further analysis into the possible “secretion”mechan-
isms of these intracellular proteins would be of interest.
Two proteins, GSN and ALDH1A1, were chosen for siRNA
silencing based on fold difference and p value. GSN is a calcium-
binding protein, which binds to and regulates actin filaments.
GSN binds to the barbed ends of actin filaments and prevents
capping [19]. Severing and capping of actin filament enhancethe rate of cell motility and migration [20]. Gelsolin is located
intracellularly in the cytoplasmandmitochondria [21] aswell as
extracellularly in the blood plasma [22]. The intracellular form,
termed cytoplasmic, and the secreted form, termed plasma
GSN, are derived from a single gene by alternative transcription
initiation sites and differential sequencing [23]. Plasma GSN
differs from cytoplasmic GSN, in that it is larger, contains 25
extra amino acids at its NH2 terminus, and is more positively
charged [24], suggesting that it is synthesised more rapidly or
catabolised more slowly [25]. Plasma GSN is removed from the
cells more rapidly, consistent with a secreted protein, and only
the plasma form of GSN is secreted in HepG2, a human
hepatoma-derived cell line. Expression of GSN was lowest in
theCMof the high invasive cell line, Clone #3, andhighest in the
CMof thepoorly invasiveClone#8. RNAi technologywasused to
study GSN protein function in CM#8. Using two independent
GSN-siRNA target sequences, GSN protein expression was
specifically down-regulated in Clone #8 cells, resulting in
decreased expression of GSN. Addition of CM from GSN-siRNA
transfected Clone #8 cells into the invasion chamber, increased
invasion of Clone #8. Our results suggest that GSN has
functional effects on invasion in Clone #8 cells. Decreased
expression of GSN has been detected in several types of human
cancers, including urinary bladder carcinogenesis [26], NSCLC
[27], prostatic adenocarcinoma [28], breast [29] and ovarian
cancer [30], suggesting a possible role as a tumour suppressor.
Our results suggest that the invasion-inhibitory effects of CM#8
may be in part due to GSN expression. GSN expression
suppresses the activation of phospholipase C (PLC)/protein
kinase C (PKCs) involved in phospholipid signalling pathways,
thus inhibiting cell proliferation and tumourigenicity [31].
Furthermore, Tanaka et al. [32] functionally knocked down
GSNexpressionbysiRNA in thehumanmammaryepithelial cell
line,MCF10A, and suggested thatGSN functions as a switch that
controls E- and N-cadherin conversion via the transcription
factor Snail. GSN knockdown led to an epithelial to mesench-
ymal transition, characterised by fibroblastic morphology, loss
of contact inhibition, focus formation inmonolayer growth and
enhancedmotility and invasiveness in vitro. Therefore, silencing
GSN expression could possibly lead to tumour progression.
However, GSN over-expression in 56% of breast cancers was
shown to be associatedwith over-expression of EGFR andHER2,
as well as a more aggressive phenotype [33]. High GSN levels
have also been identified as a negative prognostic factor in
pulmonary carcinomas, stage I non-small cell lung carcinomas
[34], where they have been linked to enhanced cellularmotility.
In pancreatic cancer, Ni et al [35] found reduced GSN expression
in 71% (30/42) of pancreatic cancer cases compared to matched
control tissues by immunohisochemistry. This reduction
seemed to be dependent on the ubiquitin–proteasome depen-
dent degradation of GSN. However, GSN expression was higher
in lymph node positive pancreatic cancers compared to lymph
node negative tumours. Thompson et al [36] reported that high
levels of nuclear GSN correlated with reduced patient survival
time, signifying re-emergence of GSN during the most aggres-
sive metastatic stages of pancreatic cancer. Reduction in the
level of GSN in pancreatic cancer cells decreased themotility of
the cells, which differs from our results; the up-regulation of
motility-modulating actin-capping proteins in pancreatic can-
cer cells may have different consequences for the motility of
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study found GSN expression in the MiaPaCa-2 cell line, and
showed that down-regulation of GSN decreasedmotility. In our
model, both cytoplasmic and plasma GSN were detected by
western blot and 2D-DIGE from the conditionedmedia of Clone
#8, the less invasive clonal population of MiaPaCa-2. Clone #8 is
a clonal population of MiaPaCa-2, with very different properties
fromClone#3, isolatedat thesame time. Furthermore,we found
that down-regulation of plasma GSN expression in CM#8
increased invasion of Clone #8 cells. Thompson et al [36]
detected cytoplasmic/nuclear expression of GSN in pancreatic
cancer tissue specimens and cytoplasmic GSN in pancreatic
cancer cell lines. The differences in the GSN isoforms detected
between the two studies may explain why differing effects on
invasion andmigrationwere observed, however further studies
are required to specifically clarify the roles of cytoplasmic and
plasma GSN on migration and invasion in pancreatic cancer. A
study detailing antibody microarray profiling of combined
serum proteins associated with pancreatic cancer, showed a
significant reduction of plasmaGSN in pancreatic cancer serum
compared to healthy controls [37], and plasma GSN expression
was also decreased in lung cancer serumby proteomic profiling
[38]. The mechanism by which GSN stimulates invasion by
interacting extracellularly with cancer cells as detailed is not
known. To further characterise function of GSN in this system,
experiments involving addition of recombinant GSN protein
into CM#3 would be valuable, but highly purified GSN would be
needed to generate useful results.
A novel protein identified as promoting the invasive abilities
of pancreatic cancer cells is aldehyde dehydrogenase 1A1
(ALDH1A1). ALDH1A1 is an enzyme, belonging to the aldehyde
dehydrogenase family of proteins which are involved in the
conversion of aldehydes to their corresponding acids byNAD(P)+
dependent reactions [39]. ALDH1A1 is a cytosolic enzyme found
in many tissues, including brain [40] and red blood cells [41].
ALDH1A1 expression has also been implicated in drug resis-
tance, asALDH1A1levelswerehigher inmetastatic tumours that
did not respond to cyclophosphamide-based treatment than
those that did respond to the regimen [42]. ALDH1A1 expression
has also been reported in the lung cancer cell line, A549, where
its expression along with ALDH1A3 was knocked down by RNAi
and implicated in cyclophosphamide resistance [43]. Jelski et al.
[44] also found that ALDH is expressed in pancreatic cancer cells
and furthermore ALDH could also be detected in the sera of
pancreatic cancer patients, although not significantly different
between pancreatic cancer patients and healthy controls [45].
ALDH1A1 is highly expressed in CM#3 compared to CM#8.
ALDH1A1 expression was reduced in CM#3 through siRNA
targeting three independent sequences of the ALDH1A1 gene.
Addition of CM from ALDH1A1-siRNA transfected Clone #3
cells into the invasion chamber reduced invasion of Clone #3
cells. This is the first time that ALDH1A1 has been reported as
a protein involved in pancreatic cancer cell invasion. Further
research will be required to determine its role in the clinical
setting.
The expression ofGSNandALDH1A1determinedbywestern
blot in the human pancreatic cancer cell lines, BxPc-3, Panc-1
and AsPc-1 corresponded to the invasive properties of the cells.
A larger panel of pancreatic cancer cell lines would be required
to confirmthe linkbetween theexpressionof theseproteinsandinvasion status in pancreatic cancer. Han et al [46] found that
GSN mRNA is expressed at low levels in a panel of nine
pancreatic cancer cell lines compared to the normal pancreas
using cDNAmicroarrays.
In conclusion, identification of released proteins from
cancer cell lines may serve as an efficient method in the
establishment of a panel of potential therapeutic targets and
biomarkers correlating to invasion/metastatic cascade of
pancreatic cancer. Future work will include examining the
sera of pancreatic cancer patients to further demonstrate if
GSN and ALDH1A1 have a diagnostic potential as biomarkers
for pancreatic adenocarcinoma.Acknowledgement
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